|
|
||||||||
Section of Cardiology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
Accepted for publication June 22, 2007.
* Address correspondence to Dr Bhagirath, c/o Dr Tam, Y3005–409 Tache Ave, Winnipeg, Manitoba, R2H 2A6, Canada (Email: umbhagir{at}cc.umanitoba.ca).
Protein-losing enteropathy is a well-known complication after the Fontan procedure, and unfractionated heparin therapy has been tried with some success as a potential therapy. Low-molecular weight heparin is believed to be ineffective. We now describe a case in which an adult patient with protein-losing enteropathy after Fontan palliation was successfully treated with systemic doses of low-molecular weight heparin, with complete resolution in the 24-hour fecal alpha-1 anti-trypsin level and serum albumin. The patient continues to remain in remission with this therapy. In conclusion, these findings are novel and compel us to re-evaluate our pathophysiologic understanding of this difficult condition.
This article has been cited by other articles:
![]() |
D. Thacker, A. Patel, K. Dodds, D. J. Goldberg, E. Semeao, and J. Rychik Use of Oral Budesonide in the Management of Protein-Losing Enteropathy After the Fontan Operation Ann. Thorac. Surg., March 1, 2010; 89(3): 837 - 842. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |